This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. McALLEN, Texas (Border Report) — A new study ...
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2025 /PRNewswire/ — IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted ...
9d
Collaboration with after-hours house-call services eases burden on home care physicians, study finds
Researchers at University of Tsukuba report that collaboration between home health care institutions and private after-hours ...
Site burden has always been a trending topic in clinical research. What is the impact on study startup? One major issue is that protocol design fails to consider site workflows. When trials are ...
US-based clinical research company Advarra has introduced Study Collaboration, a solution designed to expedite study startup by automating workflows. The solution is intended to enhance partnerships ...
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new research study sponsored by Tempus and ...
Entered into Clinical Study Collaboration and Supply Agreement with Gilead to evaluate IDE397, IDEAYA's MAT2A inhibitor, in combination with sacituzumab-govitecan-hziy ("Trodelvy") Gilead's Trop-2 ...
Entered into an additional clinical study collaboration and supply agreement with Gilead to evaluate IDE397, IDEAYA's MAT2A inhibitor, in combination with Trodelvy, Gilead's Trop-2 directed ADC, in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results